NDAINTRAVENOUSPOWDER
Approved
Jan 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
TIGECYCLINE (tigecycline) by Accord Biopharma. Approved for bacterial pneumonia, complicated intra-abdominal infections, complicated skin and skin structure infections and 3 more indications. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tigecycline is a broad-spectrum IV antibiotic indicated for complicated bacterial infections including intra-abdominal infections, skin and soft tissue infections, and community-acquired bacterial pneumonia. It is a tetracycline-class antibiotic administered as an IV powder formulation. The drug works through inhibition of bacterial protein synthesis.
Peak
Product is in peak commercialization phase with modest market presence ($597K spending) competing in a crowded hospital-based antibiotic market; team size likely mid-sized given IV specialty positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on TIGECYCLINE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.